Delivery Order SPE2DB25D3404-SPE2DB25FUQFX
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 29, 2025, with completion expected by September 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on July 21, 2025, with an ultimate completion date of August 11, 2025. The contract, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitively awarded procurement from the company's existing pharmaceutical supply agreement...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg tablets (7-count packaging) with a firm fixed price arrangement. The contract, which was competitively awarded without a set-aside designation, carries an ultimate completion date of September 11, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Ibrance 125 mg capsules (21-count packaging) under a firm fixed-price contract with a ceiling value of $8,118.08. This non-set-aside award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999 prime vendor agreement designated SPE2DX and running through December 2026. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the prime contractor, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Ibrance 75 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,123.96. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, was competitively awarded with no set-aside designation. This delivery order is issued under...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUQFXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count package) under a firm fixed price contract. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen Drug Corp's broader Indefinite Delivery/Indefinite Quantity (IDIQ) agreement with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime contract vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through this comprehensive global pharmaceutical support contract. The IDIQ vehicle enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Ibrance, an oncology medication, represents one of the specialized pharmaceutical products routinely procured through this contract vehicle to support military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/8/25 |